Literature DB >> 18692448

Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase.

Robert A Parise1, Mohammad Shawaqfeh, Merrill J Egorin, Jan H Beumer.   

Abstract

ABT-888, a poly(ADP-ribose) polymerase (PARP) -inhibitor in clinical trials, potentiates DNA-damaging agents. We developed and validated, according to FDA guidelines, an LC-MS assay for sensitive, accurate and precise quantitation of ABT-888 and its metabolite M8 in 0.2 mL human plasma. After ethyl acetate extraction, separation is achieved with a hydro-Synergi column and a 0.1% formic acid in acetonitrile/water-gradient. Detection uses electrospray, positive-mode ionization mass spectrometry. Between 10 (LOQ) and 1000 ng/mL, accuracy was 95.5-98.5% for ABT-888 and 91.4-100.9% for M8, and precision was 0.1-4.9% for ABT-888 and 0-13.7% for M8. The assay is being applied to samples generated in several clinical trials.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18692448      PMCID： PMC2634284          DOI： 10.1016/j.jchromb.2008.07.032

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN： 1570-0232            Impact factor:   3.205


  2 in total

Review 1.  PARP inhibitors for cancer therapy.

Authors:  Nicola J Curtin
Journal:  Expert Rev Mol Med       Date:  2005-03-15       Impact factor: 5.600

2.  ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Authors:  Cherrie K Donawho; Yan Luo; Yanping Luo; Thomas D Penning; Joy L Bauch; Jennifer J Bouska; Velitchka D Bontcheva-Diaz; Bryan F Cox; Theodore L DeWeese; Larry E Dillehay; Debra C Ferguson; Nayereh S Ghoreishi-Haack; David R Grimm; Ran Guan; Edward K Han; Rhonda R Holley-Shanks; Boris Hristov; Kenneth B Idler; Ken Jarvis; Eric F Johnson; Lawrence R Kleinberg; Vered Klinghofer; Loren M Lasko; Xuesong Liu; Kennan C Marsh; Thomas P McGonigal; Jonathan A Meulbroek; Amanda M Olson; Joann P Palma; Luis E Rodriguez; Yan Shi; Jason A Stavropoulos; Alan C Tsurutani; Gui-Dong Zhu; Saul H Rosenberg; Vincent L Giranda; David J Frost
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531
  2 in total
  18 in total

1.  Phase I study of veliparib in combination with gemcitabine.

Authors:  Ronald Stoller; John C Schmitz; Fei Ding; Shannon Puhalla; Chandra P Belani; Leonard Appleman; Yan Lin; Yixing Jiang; Salah Almokadem; Daniel Petro; Julianne Holleran; Brian F Kiesel; R Ken Czambel; Benedito A Carneiro; Emmanuel Kontopodis; Pamela A Hershberger; Madani Rachid; Alice Chen; Edward Chu; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2017-08-02       Impact factor: 3.333

2.  A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.

Authors:  Shivaani Kummar; Jiuping Ji; Robert Morgan; Heinz-Josef Lenz; Shannon L Puhalla; Chandra P Belani; David R Gandara; Deborah Allen; Brian Kiesel; Jan H Beumer; Edward M Newman; Larry Rubinstein; Alice Chen; Yiping Zhang; Lihua Wang; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow
Journal:  Clin Cancer Res       Date:  2012-02-03       Impact factor: 12.531

3.  The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Authors:  Jacob D Soumerai; Andrew D Zelenetz; Craig H Moskowitz; M Lia Palomba; Paul A Hamlin; Ariela Noy; David J Straus; Alison J Moskowitz; Anas Younes; Matthew J Matasar; Steven M Horwitz; Carol S Portlock; Jason A Konner; Mrinal M Gounder; David M Hyman; Martin H Voss; Matthew G Fury; Devika Gajria; Richard D Carvajal; Alan L Ho; Jan H Beumer; Brian Kiesel; Zhigang Zhang; Alice Chen; Richard F Little; Christine Jarjies; Thu O Dang; Fallon France; Nishant Mishra; John F Gerecitano
Journal:  Clin Cancer Res       Date:  2017-03-17       Impact factor: 12.531

Review 4.  PARP and PARG inhibitors--new therapeutic targets in cancer treatment.

Authors:  Nilufer Jasmine Selimah Fauzee; Juan Pan; Ya-lan Wang
Journal:  Pathol Oncol Res       Date:  2010-04-12       Impact factor: 3.201

5.  Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion.

Authors:  Hariom Yadav; Ji-Hyeon Lee; John Lloyd; Peter Walter; Sushil G Rane
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

6.  Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.

Authors:  Silpa Nuthalapati; Wijith Munasinghe; Vincent Giranda; Hao Xiong
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

7.  Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.

Authors:  Bhavana Pothuri; Allison L Brodsky; Joseph A Sparano; Stephanie V Blank; Mimi Kim; Dawn L Hershman; Amy Tiersten; Brian F Kiesel; Jan H Beumer; Leonard Liebes; Franco Muggia
Journal:  Cancer Chemother Pharmacol       Date:  2020-02-13       Impact factor: 3.333

8.  Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry.

Authors:  Richard Wiegand; Jianmei Wu; Xianyi Sha; Patricia LoRusso; Jing Li
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-11-27       Impact factor: 3.205

9.  Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.

Authors:  Renu Singh; Shailly Mehrotra; Mathangi Gopalakrishnan; Ivana Gojo; Judith E Karp; Jacqueline M Greer; Alice Chen; Richard Piekarz; Brian F Kiesel; Jogarao Gobburu; Michelle A Rudek; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2018-11-20       Impact factor: 3.333

10.  A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Authors:  Ivana Gojo; Jan H Beumer; Keith W Pratz; Michael A McDevitt; Maria R Baer; Amanda L Blackford; B Douglas Smith; Steven D Gore; Hetty E Carraway; Margaret M Showel; Mark J Levis; Amy E Dezern; Douglas E Gladstone; Jiuping Jay Ji; Lihua Wang; Robert J Kinders; Marie Pouquet; Ismail Ali-Walbi; Michelle A Rudek; Weijie Poh; James G Herman; Larry M Karnitz; Scott H Kaufmann; Alice Chen; Judith E Karp
Journal:  Clin Cancer Res       Date:  2016-08-08       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.